PaySign (PAYS) AI Stock Analysis

• Market Cap: $305.48M
• Dividend Yield: N/A
• Average Volume (3M): 1.08M
• Price to Earnings (P/E): 46.3
• Beta (1Y): 1.87
• Revenue Growth: 27.84%
• EPS Growth: -13.78%
• Country: US
• Employees: 173
• Sector: Technology
• Sector Strength: 98
• Industry: Software - Infrastructure
• EPS (TTM): 0.02
• Shares Outstanding: 54,451,890
• 10 Day Avg. Volume: 1,156,656
• 30 Day Avg. Volume: 1,081,940
• PEG Ratio: -1.05
• Price to Book (P/B): 5.28
• Price to Sales (P/S): 2.75
• P/FCF Ratio: 11.94
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: 4.46
• Enterprise Value/Gross Profit: 7.43
• Enterprise Value/Ebitda: 23.73
• 1Y Price Target: $8.50
• Price Target Upside: 51.52% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 66 Neutral
• Price Target: $6.50 ▲(15.86% Upside)

PaySign's overall stock score is driven by strong financial performance and positive earnings call highlights, particularly in the patient affordability segment. However, technical analysis indicates bearish momentum, and the high P/E ratio suggests valuation concerns. The challenges in the plasma segment also pose risks, balancing the positive growth outlook.

Positive Factors

Financial Performance

PaySign Inc. reported results that beat consensus on revenue and core adjusted EBITDA, driven by the acquisition of rights to manage payments for additional plasma centers.

Growth Outlook

Paysign's growth outlook remains very positive driven by its Pharma Patient Affordability business segment and a recent large new business award within the Plasma segment.

Strategic Expansion

Paysign announced the acquisition of Gamma Innovation, which offers technology-driven donor engagement app, a specialized CRM platform, and donor management solutions for the Plasma segment.

Negative Factors

Industry Challenges

Plasma revenue declined for two consecutive quarters due to an industry-wide oversupply in plasma inventories.

Plasma Revenue Decline

Plasma revenue declined 9.2% to $9.4 million due to reduced revenue per plasma center, reduced plasma donations and lower dollars loaded to cards.

PaySign Business Overview & Revenue Model

Company Description

PaySign, Inc. (PAYS) is a financial technology company specializing in digital payment solutions, primarily focusing on prepaid card programs and payment processing services. The company serves various sectors, including healthcare, retail, and e-commerce, providing innovative payment solutions designed to enhance consumer engagement and operational efficiency. PaySign's core products include prepaid debit cards, payment processing platforms, and mobile payment solutions, tailored to meet the needs of businesses and individuals alike.

How the Company Makes Money

PaySign generates revenue through multiple streams, primarily from transaction fees associated with the use of its prepaid card programs and payment processing services. The company earns a percentage of each transaction processed, which varies based on the type of service provided. Additionally, PaySign charges fees for card issuance, monthly maintenance, and other ancillary services related to its prepaid card offerings. Strategic partnerships with healthcare providers, businesses, and financial institutions significantly contribute to its earnings by expanding its customer base and enhancing service offerings. Furthermore, the company may also generate revenue from interest earned on stored funds and other financial services related to its payment solutions.

PaySign Financial Statement Overview

Summary

PaySign demonstrates strong revenue growth and improving operational efficiency. Despite some pressure on net profitability, the company maintains a healthy balance sheet with low leverage and strong cash flows, positioning it well for future growth and stability. However, the relatively low net profit margin and stockholders' equity warrant careful monitoring to ensure long-term financial health.

Income Statement

PaySign showed a strong revenue growth of 23.5% over the past year, indicating a positive trajectory. The gross profit margin stands at 55.1%, which is solid for the industry. However, the net profit margin has decreased to 6.5% from 13.7% last year, indicating some profitability pressure. The EBIT margin has improved to 1.7%, recovering from negative figures in prior years, showing signs of operational improvement.

Balance Sheet

The debt-to-equity ratio is low at 0.1, indicating minimal leverage, which is beneficial for financial stability. Return on equity is 12.5%, showing reasonable profitability relative to shareholder equity. The equity ratio is 17%, which is moderate and suggests a balanced capital structure. However, the stockholders' equity is relatively low compared to total liabilities, indicating potential risk if liabilities increase.

Cash Flow

Operating cash flow increased to $22.9 million, showcasing robust cash generation capabilities. Free cash flow also showed growth, which is a positive sign for future investments and debt servicing. The operating cash flow to net income ratio is high at 6.0, indicating strong cash conversion efficiency. The free cash flow to net income ratio is 5.9, reinforcing the company's strong cash position relative to earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	68.54M	58.38M	47.27M	38.03M	29.46M	24.12M
Gross Profit	41.12M	32.20M	24.14M	20.95M	14.71M	9.30M
EBITDA	12.88M	7.02M	3.86M	3.25M	-213.22K	-5.79M
Net Income	6.78M	3.82M	6.46M	1.03M	-2.72M	-9.14M
Balance Sheet
Total Assets	193.90M	179.03M	146.60M	108.24M	84.05M	67.83M
Cash, Cash Equivalents and Short-Term Investments	11.75M	10.77M	16.99M	9.71M	7.39M	7.83M
Total Debt	2.72M	2.93M	3.31M	3.67M	4.01M	4.33M
Total Liabilities	151.69M	148.59M	122.11M	91.95M	71.06M	54.60M
Stockholders Equity	42.21M	30.44M	24.49M	16.29M	12.99M	13.24M
Cash Flow
Free Cash Flow	-13.26M	13.46M	20.57M	21.23M	12.55M	10.43M
Operating Cash Flow	-8.24M	22.95M	27.62M	25.32M	15.23M	13.78M
Investing Cash Flow	-11.10M	-9.49M	-7.05M	-4.09M	-2.68M	-3.34M
Financing Cash Flow	-274.50K	-466.25K	-1.12M	0.00	192.14K	-72.86K

PaySign Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.61
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PAYS, the sentiment is Neutral. The current price of 5.61 is below the 20-day moving average (MA) of 7.31, below the 50-day MA of 6.60, and above the 200-day MA of 3.84, indicating a neutral trend. The MACD of -0.29 indicates Positive momentum. The RSI at 34.51 is Neutral, neither overbought nor oversold. The STOCH value of 20.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PAYS.

PaySign Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PAYO	74 Outperform	$2.39B	25.22	13.86%	―	13.02%	-2.57%
IMXI	72 Outperform	$278.18M	5.48	36.15%	―	-0.09%	-3.52%
PAYS	66 Neutral	$305.48M	46.29	19.65%	―	27.84%	-13.78%
PRTH	63 Neutral	$562.62M	27.06	57.39%	―	12.86%	―
Sector *	61 Neutral	$35.87B	6.13	-9.30%	2.06%	7.63%	-6.38%
KPLT	58 Neutral	$56.49M	―	86.76%	―	9.71%	-1.97%
BKKT	44 Neutral	$213.78M	―	-60.94%	―	128.83%	73.67%

PaySign Corporate Events

PaySign Stockholders Approve Key Proposals at Annual Meeting

On May 7, 2025, PaySign held its annual meeting of stockholders to vote on several key proposals. The stockholders elected seven directors to the board, approved executive compensation on a non-binding advisory basis, and decided to hold advisory votes on executive compensation every three years. Additionally, Moss Adams LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (PAYS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on PaySign stock, see the PAYS Stock Forecast page.